News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Real-world data in Japan: 1L/2L palbociclib-ET effective in HR-positive/HER2-negative advanced breast cancer
13 May 2024
bySarah Cheung
Palbociclib combined with endocrine therapy (ET) is effective in hormone receptor (HR)–positive, HER2-negative advanced breast cancer (ABC) in both first-line (1L) and second-line (2L) settings in the real world, a multicentre observational study in Japan has shown.








